Persistent Depersonalization/Derealization Disorder Induced by Synthetic Cannabinoids
Tothe Editor: Depersonalization/derealization disorder is characterized in DSM-5 by persistent or recurrent depersonalization symptoms in the presence of intact reality testing, not better accounted for by other psychiatric or medical disorders. Its prevalence is around 2% in the general population (1). Depersonalization/derealization disorder is underdiagnosed by clinicians and is particularly resistant to pharmacological treatments (2). In a substantial number of cases, the onset is triggered by cannabis, hallucinogens, 3,4-methylenedioxymethamphetamine (Ecstasy), LSD, and ketamine consumption (1, 3). We report the case of Mr. A, a 20-year-old male student who used cannabis on a weekly basis from ages 18 to 19 and who was without a history of substance use disorder or other psychiatric disorders.
In November 2014, following a single dose of the synthetic cannabinoid K2, without any other associated drug, Mr. A immediately presented with symptoms reflective of depersonalization/derealization disorder. He described a detachment from his own thoughts, body, and feelings and his impression “of not being there.” He also reported the feeling of being disconnected from his own body, “as if his mind were outside his body,” without reaching out-of-body experience. The emotional numbing was paradoxically associated with very painful feelings. Derealization was also reported as he had the impression “of being in a dream.” The patient was aware of a disturbing change in his experience of himself and his surroundings. His sense of reality was intact.
The patient asked for help nearly 6 months later, noting continuing unrest even though he immediately stopped using K2 and cannabis. He fulfilled the DSM-5 criteria for depersonalization/derealization disorder.
The patient’s results on the Cambridge depersonalization scale (1) were scored as 220/290. His symptoms caused significant distress and impairment in social and occupational functioning and were not better categorized under another mental disorder. There were no symptoms of a psychotic disorder, anxiety, or depressive mood disorder, as classified by DSM-5. Results of an electroencephalogram and brain imaging were normal, and results of a subsequent urine analysis were negative. He received fluoxetine treatment for 6 months without any improvement. The symptoms remained persistent for more than 17 months.
Discussion
To our knowledge, this is the first case report of depersonalization/derealization disorder induced by K2 use. This case highlights the severity of depersonalization/derealization disorder induced by K2. Despite their lack of structural similarity with Δ9-tetrahydrocannabinol (THC), the psychoactive components of K2 are agonists of the CB1 cannabinoid receptors, with a higher binding affinity than Δ9-THC (4), which could explain the severity of the patient’s symptoms. K2 is a hybrid herbal/chemical product that is easily available on the web and not detected by standard drug tests. The belief that it is harmless may be contributing to its increasingly widespread use among young people (4).
1 : Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. J Clin Psychiatry 2009; 70:1358–1364Crossref, Medline, Google Scholar
2 : Depersonalization disorder: pharmacological approaches. Expert Rev Neurother 2008; 8:19–26Crossref, Medline, Google Scholar
3 : Cannabis-induced depersonalization disorder in adolescence. Neuropsychobiology 2012; 65:141–146Crossref, Medline, Google Scholar
4 : Here today, gone tomorrow ... and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones, Salvia divinorum, and piperazines. J Med Toxicol 2012; 8:15–32Crossref, Medline, Google Scholar
